Funded project
Equity
Hyperspectral Imaging for AD

Hyperspectral Imaging for AD

Neurodegeneration
Early diagnostics
Alzheimer’s Disease
Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality and response to insult, hence, the eye providing a unique window to the central nervous system.
Funding
30,000 EUR
Initiated
24.5.2022
Approval
98.47% Voted Yes
No items found.
AT A GLANCE

Stage: Pre-seed prototype stage

Area: Diagnostics

Status: Ongoing

Patent: Two patents on the camera technology secured (P436042SE00 & SE542835C2)

PROJECT LINKS

Background

Alzheimer’s Disease is the main cause of dementia worldwide. There is currently no easy way to diagnose it. As a result, patients get diagnosed too late, once their cognitive decline has started. Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology. Hence, the eye provides a unique window to the central nervous system without the need for expensive, invasive, and/or potentially harmful examinations.

Aims, Hypothesis & Results

This camera will fit on a fundoscope routinely used by opticians and ophthalmologists. It will be developed to detect patients with high levels of amyloid up to 15 years before their cognitive ability declines. Earlier diagnosis will considerably increase chances to adopt a healthy lifestyle to reduce/postpone the risk of getting Alzheimer as well as increasing the chance of getting treatment in time.


Timeline

  • Developing improved version of the camera
  • Clinical and preclinical verification testing

Required Funding: €30000
Status: Ongoing
Duration: 24 Months

Measuring amyloid plaques in the brain directly with amyloid PET scan. This is a lengthy and costly procedure. FDA approved retinal camera by Optina (FDA 510(k) clearance for its Mydriatic Hyperspectral Retinal Camera (MHRC-C1) in 2020). This camera uses its own light source; it cannot be mounted on a fundoscope and is very expensive. Estimated at >50k Euro, hindering mass adoption. Mantis Photonics is developing a hyperspectral camera that can be easily added to routine fundoscopy at opticians and ophthalmologists for the detection of amyloid deposits in the retina. There is peer-reviewed proof-of-concept research supporting hyperspectral retinal imaging to classify AD patients vs controls. The team is seeking bridge funding until their seed round later this year to collect in vivo data in mice/humans of their camera.

VitaDAO Board Evaluation Writeup

The retina amyloid detection camera is already FDA approved and there is peer-reviewed proof-of-concept research supporting hyperspectral retinal imaging to classify AD patients. The project has future potential to become a platform diagnostic for several aging related and other conditions: AMD, diabetic retinopathy, etc. The team is strong with extensive scientific expertise in the field. The current valuation of Mantis Photonics is low ($3-4M). The product is still in the prototype stage and more data is needed on its performance in mice and humans.

Projects supported

Non Consectetur Necessitatibus

Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

$293,00
raised
View Project

Dolorum Quia

Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

$293,00
raised
View Project

Eum Harum Asperiores Id

Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

$293,00
raised
View Project

Ex Temporibus Perferendis

Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

$293,00
raised
View Project

Culpa Possimus

Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

$293,00
raised
View Project

Earum Est Dolorem

Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

$293,00
raised
View Project

Aperiam Et Quis Et

Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

$293,00
raised
View Project

Voluptas Quam Sapiente

Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

$293,00
raised
View Project

Aut Accusantium Ut

Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

$293,00
raised
View Project

Nisi

Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l

$293,00
raised
View Project
Latest Project Updates
No items found.
24
May
2022
Project Initiated!

Discover more projects & initiatives

ApoptoSENS - Senolytic CAR-NK Cells

IP-NFT

Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.

$ 253,000
raised
View Project

Scheibye-Knudsen Lab

IP-NFT

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
raised
View Project

Discovery of novel mitophagy activators for Alzheimer’s disease

IP-NFT

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
raised
View Project

Turn Biotechnologies

Equity

Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.

$ 1,000,000
raised
View Project

Are you working on the next longevity science breakthrough?

Apply for funding

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?